XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp.
- ISIN: CA98421R1055
- Land: .
Nachricht vom 06.12.2019 | 22:05
XPhyto Therapeutics Developing Epilepsy Treatment with Oral Thin Film Delivery System
DGAP-News: XPhyto Therapeutics Corp.
/ Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the development of Epilepsy treatment products using its proprietary oral thin film delivery system will be a priority initiative for 2020. The Company is focusing on generic cannabidiol-based dissolvable oral wafers for the treatment of severe childhood forms of Epilepsy, specifically Dravet syndrome ("Dravet") and Lennox-Gastaut syndrome ("LGS").
Current FDA/EMA-approved cannabidiol-based treatment for Dravet and LGS is founded on a plant extract oil containing 100mg of cannabidiol (CBD) per milliliter. Based on initial dissolution testing using XPhyto's proprietary thin film drug delivery system, previously announced on November 11, 2019, the Company's oral delivery system may yield as much as a 10-20x increase in bioavailability of CBD over existing oil delivery methods.
To view an enhanced version of Figure 1, please visit:
"XPhyto believes that an efficient and well-defined dosage form is the future of cannabis-based medicine. High bioavailability with controlled and reproducible delivery is critical," said Hugh Rogers, CEO of XPhyto. "Our initial results suggest significant potential timing and efficiency advantages over conventional delivery methods."
XPhyto's thin film drug delivery system was developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Vektor is a narcotics manufacturer, importer, and researcher located near Munich, Germany. Vektor's previous development work has included narcotics delivery systems for conventional oncology and non-oncology pain treatment, such as Fentanyl, Hydromorphone, and Oxycodone, and more recently, the development of efficient cannabis delivery and dosage systems.
Oral thin film drug delivery is a large and growing international industry which provides an alternative to conventional solid and liquid oral dosage forms. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.984 billion by 2024 and rising at a solid 9.0% CAGR between 2019 and 2024.
About XPhyto Therapeutics Corp.
XPhyto is a next-generation cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). Bunker has two exclusive R&D collaboration agreements with the Technical University of Munich, Faculty of Chemistry as well as the Chair of Beverage and Brewing Technology. XPhyto acquired 100% of Vektor Pharma TF GmbH, a German narcotics manufacturer, importer and researcher with expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. XPhyto is pursuing additional opportunities in Germany including commercial cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
For further information, please contact:
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; research and development results may not be positive; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50530
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/50530
News Source: Newsfile
|Company:||XPhyto Therapeutics Corp.|
|EQS News ID:||930821|
|End of News||DGAP News Service|
UmweltBank AG mit deutlichem Kurspotenzial
Die UmweltBank AG, die als einzige Bank Deutschlands den Umweltgedanken in der Satzung verankert hat, präsentierte in den letzten Jahren beeindruckende Wachstumszahlen. Sowohl die Kundeneinlagen als auch das Kreditbuch legten um durchschnittlich gut 6,3 % zu. Seit seiner Gründung hat das Kreditinstitut stets positive Ergebnisse erzielt, zuletzt im Geschäftsjahr 2018 einen Jahresüberschuss in Höhe von 25,3 Mio. €. Wir haben ein Kursziel von 14,30 € je Aktie ermittelt, was deutlich oberhalb des aktuellen Kursniveaus liegt. Die Dividendenrendite liegt bei fast 3,0 %.
Der AKTIONÄR News
27. Januar 14:40 Spekulativer AKTIONÄR-Tipp geht auf: "Pandemie-Aktien" explodieren
27. Januar 14:35 DAX: Ein Hauch von Panik schwebt über das Parkett
27. Januar 14:30 Gold: Durchmarsch Richtung 2.000 Dollar?
27. Januar 14:13 Opening Bell: Dow Jones vor 400-Punkte-Absturz; Tesla, Alibaba, ...
27. Januar 14:12 10,7 Prozent – Blue Chip mit Super-Dividende
Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): BUY
27. Januar 2020